Jayesh Desai, MBBS, FRACP, discusses the evolution of divarasib, highlighting the rationale for combining the KRAS G12C inhibitor with cetuximab in patients with advanced colorectal cancer harboring KRAS G12C mutations in a phase 1b study.
Jayesh Desai, MD
Advertisement
Articles by Jayesh Desai, MD
Jayesh Desai, MD, honorary, Surgery, The Sir Peter MacCallum Department of Oncology, Clinical School-Austin Health, Royal Melbourne Hospital, discusses a phase Ia study exploring BGB-283 in patients with BRAF- or KRAS/NRAS-mutated solid tumors.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
2
TALAPRO-3 Shows Talazoparib Plus Enzalutamide Improves rPFS in HRR-Altered mCSPC
3
Selinexor Plus Ruxolitinib Yields Superior Spleen Responses, OS Signal in JAK Inhibitor–Naïve Myelofibrosis
4
Dr Eads on Early Data for CDH17-Directed CAR T-Cell Therapy in R/R GI Cancers
5